With the existing knowledge of ATM's role in therapeutic resistance, the present study aimed at identifying the molecular mechanisms that influence ATM to oscillate between chemoresistance and chemosensitivity. We observed that the redox status of tumors functions as a major determinant of ATM-dependent 'resistance-to-apoptosis' molecular switch. At a low reactive oxygen species (ROS) condition during genotoxic insult, the ATM/sumoylated-IKKc interaction induced NFjB activation that resisted JNK-mediated apoptosis, whereas increasing cellular ROS restored ATM/JNK apoptotic signaling. A search for the upstream missing link revealed that high ROS induces oxidation and ubiquitin-mediated degradation of PIASc, thereby disrupting PIASc-IKKc cross talk, a pre-requisite for IKKc sumoylation and subsequent NFjB activation. Interruption in the PIASc-mediated resistance pathway channels ATM signaling toward ATM/JNK pro-death circuitry. These in vitro results also translated to sensitive and resistant tumor allograft mouse models in which low ROS-induced resistance was over-ruled in PIASc knockout tumors, while its overexpression inhibited high ROS-dependent apoptotic cues. Cumulatively, our findings identified an unappreciated yet critical combinatorial function of cellular ROS and PIASc in regulating ATM-mediated chemosensitization of resistant tumors. Thus, therapeutic strategies employing ROS upregulation to inhibit PIASc during genotoxic therapy may, in future, help to eliminate the problems of NFjB-mediated tumor drug resistance.
Subject Category: Cancer
Genotoxic stress-induced apoptotic cell death by chemotherapy remains the core of anticancer treatment. However, despite the tremendous strides made in the development of targeted anticancer therapies, emergence of resistance to genotoxic drugs is still a major obstacle in the successful management of resistant and aggressive tumors. [1] [2] [3] Therefore, a profound investigation into the in-depth molecular mechanisms of drug resistance is essential and may hopefully translate into effective therapies that can flip the switch from drug resistance to susceptibility.
An insult to the cellular blue print by several anticancer drugs initiates an orchestrated response coordinated by sensor, transducer and effector proteins that detect the damage and activate either a repair mechanism or an apoptotic program in case of overwhelming damage. 4 A key arbiter of the DNA damage pathway is the ataxia telangiectasia mutated (Atm) gene, a member of the PI3K superfamily. 5 The ATM-dependent pathway serves as an anticancer barrier that helps to delay or prevent cancer as well as induces apoptosis upon genotoxic damage. 6, 7 However, DNA damage activates not only the well-documented pathways of DNA repair and apoptosis but also major signaling pathways of chemoresistance. [8] [9] [10] Interestingly, in contrary to tumorpreventive functions of ATM, it has been proposed that ATM inhibition might provide a general strategy to sensitize tumors to the cytotoxic effects of DNA-damaging therapies by preventing the execution of critical survival programs. 8 Supporting this view, primary cells from ataxia telangiectasia (A-T) patients, ATM-knockout mice and ATM-deficient tumors have been found to be hypersensitive to ionizing radiation (IR) and chemotherapy-induced DNA double-strand breaks. 9, 10 However, the dearth of information for the molecular basis of ATM's decision to optimize resistance or apoptosis may have necessarily contributed to the failure of reputed genotoxic therapies. Therefore, knowledge of molecular phenomena that governs the oscillation of ATM between resistance and apoptosis to finally activate one of them is pivotal in improving therapeutic responses in drug-resistant cancer cells.
Very recently, the role of oxidative stress in regulating the chemosensitivity of cancer cells has gained immense recognition. 11 Experimental evidence supports the fact that reactive oxygen species (ROS) has an important role as signaling molecules in diverse physiological processes. 12 Indeed, low levels of ROS have been linked to cellular proliferation and drug resistance, which provides an explanation for the pro-oxidant state invariably associated with the transformed phenotype. 13, 14 In fact, mild-to-moderate levels of ROS have often been found to trigger pro-survival responses in vitro by the activation of mitogen-activated protein kinases (MAPKs), thereby contributing to resistance against therapy. 15 In contrast, higher levels of ROS stimulated multiple death pathways, namely, typical and atypical apoptosis, necrosis and so on, thereby enhancing the therapeutic efficiency. [16] [17] [18] [19] Therefore, a novel approach in enhancing tumor cell sensitivity to genotoxic stress would be to favorably tailor the redox status of cancer cells to restrain resistance and to allow efficient execution of drug-dependent apoptosis.
Our studies with different resistant and sensitive tumor models strongly support the notion that cellular oxidative stress generated in response to genotoxic stimuli is a major factor that fine tunes the signals downstream of ATM to induce either apoptosis or resistance. Our results demonstrated that, in comparison with sensitive tumors, resistant tumor cells maintained low levels of cellular ROS, thereby surviving genotoxic insult via activation of the ATM-IKKg-NFkB resistance pathway. However, ROS beyond a certain threshold, as produced by severe genotoxic stress, induced 'resistance to apoptosis' switchover by interruption of the ATM-IKKg molecular talk, inhibition of NFkB and subsequent execution of the ATM-JNK apoptotic cascade. In-depth exploration into hitherto unexplored mechanisms revealed that oxidationmediated PIASg degradation by high ROS intervened IKKg sumoylation and hence the ATM-IKKg association, which subsequently enabled execution of ATM-dependent chemosensitization. Thus, strategies employing ROS upregulation to inhibit PIASg during genotoxic therapy may, in future, help to eliminate the problems of NFkB-mediated tumor drug resistance.
Results
ATM, upon genotoxic damage, functions as a binary switch in dictating survival versus apoptotic responses in chemoresistant cells. An effort to evaluate the chemosensitivity of different NSCLC cells revealed that A549 and NCIH1299 were highly resistant to different genotoxic drugs such as cisplatin, doxorubicin and etoposide, as compared with NCIH460 ( Figure 1a) . Interestingly, higher doses of the same drugs were able to produce a pronounced apoptosis of B60% in these resistant cells (Figures 1a and b) . These findings, therefore, indicated that resistant cells A549 and different drugs, were subjected to western blotting to determine the expression levels of p-ATM, ATM and gH2AX. a-Actin was used as internal loading control. Percent apoptosis in the ATM-siRNA transfected or KU55933 pre-exposed (c) A549 and (d) H460 cells was scored following drug treatment. The efficiencies of both genetic and pharmacological ATM depletion in (c) A549 and (d) H460 were determined by examining the expression status of p-ATM, ATM and p-Chk2. (e) Specificity of ATM knockdown was determined by scoring the percent apoptosis of siRNA-resistant ATM-cDNA-and siRNA-sensitive ATM-cDNA-expressing A549 cells transfected with ATM-siRNA following drug treatment. Values are mean ± S.E.M. of five independent experiments in each case. *Po0.01 when compared with respective control sets NCIH1299 were protected from genotoxic stress up to a certain limit, exceeding which turned on the apoptotic switch in these cells.
Consistent with the tumor-suppressive functions of ATM, [5] [6] [7] we hypothesized that ATM activation might be a general strategy for chemosensitizing resistant tumors to the cytotoxic effects of DNA-damaging therapies. Interestingly, both resistant and sensitive NSCLC cells showed ATM phosphorylation and gH2AX induction over a wide-range of genotoxic doses (Figures 1c and d) . As hypothesized, ATM silencing produced a survival benefit in both A549 ( Figure 1c ) and H460 ( Figure 1d ) cells at high dose cisplatin (60 mM). In contrast, at low dose of cisplatin (10 mM), unlike ATM-depleted H460 cells that manifested resistance (Figure 1d ), ATM-silenced A549 cells underwent apoptosis (Figure 1c ). Another sensitive breast cancer cell line, MCF-7, showed resistance to both low and high doses of different genotoxic drugs upon ATM silencing (Supplementary Figure 1) . Consistent with cisplatin treatment, ATM-depleted A549 cells manifested profound sensitivity to low dose of doxorubicin and etoposide while being resistant to high doses of the drugs, suggesting that, apart from apoptotic functions at high dose of genotoxic stress, ATM might have a significant role in chemoresistance at low dose of the stress (Figure 1c ). ATM-depletion results were further corroborated with an ATM-specific kinase inhibitor, KU55933 (Figures 1c and d) . To confirm the specificity of the ATM knockdown, siRNA-resistant ATMcDNA was transfected in resistant cells. These cells, when engineered with ATM-siRNA, failed to exhibit chemosensitizing effect upon low doses of cisplatin exposure (Figure 1e ). Levels of ATM, p-ATM and p-Chk2 (ATM substrate) were further examined to validate knockdown or inactivation of ATM function (Figures 1c and d) . These findings that ATM deficiency induces resistance at high dose, while causing apoptosis at low dose, confirm the central role of ATM as a binary switch that dictates exactly opposite tumor responses to varying degree of genotoxic stress in resistant cells.
ATM gears DNA damage responses in resistant cells toward NFjB-dependent survival or JNK-mediated apoptosis depending on the degree of genotoxic stress.
In consistence with recent evidences about a critical function of NFkB in drug resistance, 1, 20 we observed that, unlike sensitive cells that manifested cytosolic retention of p65NFkB, resistant A549 cells displayed increased nuclear accumulation of p65 subunit of NFkB at low dose (Figure 2a) . However, at high dose, which triggered apoptosis in resistant cells (Figures 1a and b) , localization of NFkB was essentially cytosolic, suggesting a role of NFkB in evading apoptosis. Our findings further demonstrated that overexpression of p65NFkB (Figure 2b . It therefore can be hypothesized that, at both low dose and high dose, ATM could have induced resistant cell apoptosis through MKK4-mediated activation of JNK, which, however, was not evident at low dose. At this juncture, therefore, the possibility of the p65NFkB pathway contributing to JNK inactivation during adaptive resistance was proposed. In support of this hypothesis, results in Figure 3c show that ATM-dependent JNK activation was possible at low dose only in the absence of functional p65NFkB, overexpression of which inhibited the same (Figure 3c ). Interestingly, MKP1, which dephosphorylates JNK, 21 was induced at both mRNA and protein levels in low dose-exposed A549 cells (Figure 3d ), whereas silencing MKP1 with specific MKP1-siRNA ensured low dose-induced JNK phosphorylation (Figure 3d ). The inability of low dose to induce MKP1 in IkBa-SR-expressing A549 cells ( Figure 3d ) further confirmed that p65NFkB inactivated JNK via MKP1 upregulation. These results clearly elucidate that, in chemoresistant cells, ATM upregulates MKP1 via p65NFkB to inhibit the ATM-induced JNK apoptotic pathway.
Degree of ROS dictates the choice of the downstream pathway. Next, our effort to understand the upstream mechanism that dictates the switchover of ATM signaling from the NFkB pathway to the JNK pathway revealed that low dose cisplatin was unable to enhance ROS levels ROS-PIASc cross talk and tumor drug resistance S Mohanty et al significantly in resistant cells as compared with sensitive cells, although high dose induced significant ROS production ( Figure 4a ). In our next approach, external manipulation of ROS levels at low dose and high dose cisplatin using H 2 O 2 (4 mM; 1 h pre-treatment) and NAC (40 mM; 12 h pretreatment), respectively, not only regulated drug responses ( Figure 4a ) but also reversed the p-ATM-IKKg interaction status (Figures 4b and c) , which has an important role in triggering p65NFkB signaling in response to DNA strand breaks. 11 To further strengthen our hypothesis that the p-ATMIKKg interaction status was subjective to ROS levels, resistant A549 cells were exposed to increasing doses of cisplatin (0-80 mM; 1 h) and Translating in vitro results in the resistant tumor allograft-bearing mouse model. To validate the in vitro results in an in vivo mouse model, we transplanted cisplatinsensitive (CS-EAC) and cisplatin-resistant (CR-EAC) Ehrlich's ascites carcinoma cells 22 into the peritoneal cavity of recipient Balb/c mice. These EACs were also resistant to structurally and functionally unrelated drugs such as doxorubicin and vinblastine. 23 After 2 weeks when extensive EAC liquid tumor formation could be observed, cisplatin treatment was started. Whereas treatment with cisplatin led to marked decrease in abdominal perimeter, tumor volume The fact that IKKg/p-ATM nuclear co-localization was subject to ROS level modulation was further confirmed by confocal imaging. (c) A549 cells were preincubated with H 2 O 2 (4 mM, 1 h)/NAC (40 mM, 12 h) followed by cisplatin treatment, and IKKg was immunopurified from cell lysates. The immunocomplex was then tested for IKKgassociated p-ATM by western blotting. In parallel, the levels of p-ATM were determined by western blotting. (d) Co-immunoprecipitation experiments were employed to determine cisplatin-induced IKKg ubiquitination in H 2 O 2 /NAC-pre-treated A549 cells. In the same experimental setup, the levels of p-IKKb, nuclear p65NFkB, p-JNK were also determined by western blotting. (e) Cell viability and ROS production up on treatment of A549 cells with a dose range of cisplatin and H 2 O 2 -treated were scored by trypan blue dye exclusion assay and flow cytometrically by measuring DCFH-DA fluorescence, respectively. (f) IKKg precipitates and nuclear lysates of cisplatin-/H 2 O 2 -treated A549 cells were subjected to western blotting to determine the amount of p-ATM and nuclear p65NFkB, respectively. a-actin and histone H1 were used as internal controls. Values are mean ± S.E.M. of five independent experiments in each case. *Po0.01 when compared with respective control sets and viable cell count of CS-EAC-implanted mice (Figures 6a and b) , CR-EACs manifested increase in abdominal perimeter, tumor volume and viable tumor cell count suggesting ineffectiveness of cisplatin treatment (Figures 6a and b) . In addition, in cisplatin-treated sets, CS-EACs showed remarkable apoptosis when compared with CR-EACs (Figure 6c ). Validating our in vitro results, unlike in sensitive cells in which cisplatin-induced significant elevation in ROS levels (Figure 6d ) was paralleled by a dominant apoptotic response via p-JNK and caspase-3 activations (Figure 6e ), cisplatin failed to significantly elevate ROS levels in resistant cells (Figure 6d) , thereby facilitating the PIASg-dependent ATM-NFkB chemoresistance pathway (Figure 6e) .
To re-validate the above-mentioned results, we took two approaches. In the first approach, sensitive EAC cells were stably transfected with an empty vector (EAC-V) or a vector-containing WT PIASg gene (EAC-P), (Figure 7a) . Next, these EAC-V or EAC-P cells were transplanted intra-peritoneally in BALB/c mice. Allografts derived from EAC-V cells furnished significant reduction in abdominal perimeter, tumor volume and viable tumor count compared with EAC-P after cisplatin treatment (Figures 7b  and c) . Furthermore, EAC-P-transplanted tumors furnished lesser apoptotic cells than EAC-V-derived tumors in cisplatin-treated groups (Figure 7d ). ROS level was not only significantly high in EAC-V than EAC-P upon cisplatin treatment (Figure 7e ) but also was positively correlated with percent apoptosis of tumor cells (Figure 7d ). In the second approach, CR-EACs were engineered to express PIASgCA clone. Consistent with our in vitro findings, mice bearing the CR-EAC-PIASgCA tumor showed significantly reduced tumor volume when compared with the CR-EAC-PIASgWT tumors upon cisplatin treatment (Figures 7f and g ). All these outcomes not only validated the in vitro data but also raised the possibility of the presence of a positive feed-back loop in resistant cancer cells where the PIASg-induced ATM-NFkB pathway created an antioxidative microenvironment 24 that, failing to sufficiently degrade PIASg, re-contributed to hypoxia-mediated chemoresistance and continued the cycle.
In gist, our in vitro and in vivo findings together establish a critical combinatorial function of cellular ROS and PIASg in cross-connecting the ATM-NFkB and ATM-JNK pathways, thereby ultimately deciding the fate of resistant cancer cells to genotoxic chemotherapy (Figure 8 ).
Discussion
This report strengthened the importance of PIASg-mediated IKKg sumoylation that channelizes genotoxic drug-induced ATM signals toward the resistance pathway at low ROS, whereas the high ROS-mediated PIASg degradation served as a pivot in driving ATM-dependent chemosensitization of drug-resistant cancer cells.
In our experimental system, as the amount of genotoxic stress-induced ROS was correlated with ATM-mediated apoptosis in otherwise resistant cancer cells, it appeared logical to draw a hypothesis that beyond a threshold level intracellular ROS functioned as the master regulator in switching over ATM's response from resistance to apoptosis. Supporting our hypothesis, few studies have described a role for ROS in various aspects of ATM function, suggesting that ATM could be a sensor of perturbations in redox homeostasis triggering the activation of various signal transduction pathways. [25] [26] [27] Certain studies suggesting that loss of ATM may correlate with resistance to DNA-damaging chemotherapy and poor patient survival 28, 29 questioned the contribution of ATM in cellular response to anticancer therapies. The general perception is that the extent of DNA damage or the downstream factor(s) may be the major issue in this decision. Support comes from the role played by tumor suppressor p53 in repairing DNA damage in response to the mild stress, whereas high doses of the same DNA-damaging agents result in p53-dependent apoptosis in an ATM-dependent manner. [30] [31] [32] However, it is yet not known as to how the extent of ROS produced during DNA damage regulates ATM function, if any, and the molecular mechanisms underlying this process. Our studies showed that at low ROS environment, which was generated by low dose of genotoxic drug, ATM activates the p65NFkB-mediated resistance pathway. However, inactivating p65NFkB directly by gene silencing or indirectly by biochemical increment of ROS restored the ATM-dependent JNK death cascade. This observation is consistent with recent studies where elevated p65NFkB activity hampers tumor cell killing by genotoxic conditions, and even a transient exposure to small doses of chemotherapy induces resistance by the activation of p65NFkB. [33] [34] [35] [36] [37] However, unlike high ROS where ATM specifically induced JNK phosphorylation and apoptosis, at low ROS, an ATM's response was open for both NFkB and JNK activation as ATM knockdown at low ROS only partially sensitized drug-resistant cells to killing by genotoxic chemotherapy, thereby leaving room for ATM's contribution also to apoptosis at low ROS, which was overpowered by p65NFkB. In fact, our subsequent search identified p65NFkB-induced MKP1 as the masking factor for JNK-1 during low dose treatment, thereby justifying our findings that, at high ROS when p65NFkB was inhibited, why ATM signal gets channelized toward the JNK-1 apoptotic pathway. In gist, despite the molecular complexity of DNA damage response networks, a simple stratification based solely on the combined status of ROS and its cross talk with ATM might help determine the response to genotoxic chemotherapy. Shifting of ATM signal from p65NFkB to JNK-1 next raises the question as to why high ROS resulted in p65NFkB inhibition. The first reason comes from the fact that, with ATM failing to bind IKKg at high ROS, the chances of PIASg not sumoylating IKKg at high ROS became favorable. Further exploration into this signaling event revealed that, in contrast to mild genotoxic stress, high ROS generated by severe DNA damage oxidized E3 SUMO ligase, PIASg, and hindered the interaction between PIASg-IKKg. Degradation of PIASg upon extensive oxidation, therefore, appeared to be the major cause behind negative regulation of the ATM-IKKg-NFkB signaling during conditions of high ROS following DNA damage. Consistently, PARP-1-, PIASg-or IKKgdeficient mouse embryonic fibroblast was strongly and equivalently sensitized to IR-induced apoptosis. 38 Interestingly, mice lacking PARP, an important component of the PARP-PIASgIKKg-ATM signalosome complex, revealed an extreme sensitivity and a high genomic instability to genotoxic agents. Supporting our findings, Luciani et al. have shown that PIASg induced Transglutaminase 2 (TG2) sumoylation, which contributed to p65NFkB-mediated inflammation at ROS levels similar to that which favored PIASg-mediated IKKg sumoylation and p65NFkB activation in our study. 39 In harmony with earlier reports where sumoylation is ROS-dependent, 40 ,41 the novelty of our finding lies in the fact that ROS though initially favorable, beyond a certain threshold becomes inhibitory for PIASg-IKKg interaction. Originally described as STAT interacting protein, PIASg is characterized by a RING-like motif with characteristic spacings of cysteines required for SUMO-E3 ligase activity. 42 Consistently, a recent study conducted by Mabb et al. 43 showed that overexpression of a catalytically inactive mutant PIASg (PIASgCA with the catalytic Cys 342 and Cys 347 mutated to alanine) inhibited sumoylation of IKKg and p65NFkB activation. Concomitantly, a comparative analysis of the structures of the kinase domains of IKKs and related kinases indicates that oxidation of Cys-179 in either IKKa or IKKb would lead to its inhibition and hence p65NFkB inactivation, suggesting that cysteine residues are at increasing risk of ROS-mediated oxidation. 44, 45 Oxidation is one of the chief causes of protein damage, subject to which proteins undergo extensive degradation. 46 On the basis of above cited literature we further propose that redox sensitive modification/ oxidation of PIASg catalytic cysteine residues and its subsequent degradation at high dose cisplatin might be the reason for inhibiting the PIASg-IKKg interaction and hence IKKg sumoylation. Of note, other roles for PIASg in regulating p65NFkB function have also been observed. In a study conducted by Albor et al., 47 PIASg inhibited transcriptional activity of NFkB in mouse keratinocyte cell line in response to combination of UV and TNFa. However, in our study though PIASg was inevitable for nuclear translocation of p65NFkB at low ROS, the p65NFkB-dependent MKP1 transcription remained unaffected by PIASg. Perhaps similar ROS levels were found to inhibit trans-repressing activity of PIASg by favoring TG2-mediated histone deacetylase 3 ubiquitination. 39 In summary, it is acknowledged that cancer cells in advanced stage tumors frequently exhibit high oxidative stress and the upregulation of antioxidant capacity in adaptation to this intrinsic oxidative stress confers drug resistance in these cells. Abrogation of such drug-resistant mechanisms by redox modulation by a combinatorial therapy of exogenous ROS-generating agents with conventional chemotherapy might be an effective strategy for eliminating these otherwise 'drug-resistant' cancer cells. The present study providing new insights into the role of ROS in deciding the 'life or death' choices of chemorefractory tumors opens up an avenue for designing 'redox modulation strategies' for chemosensitization of resistant tumors.
Materials and Methods
Cell culture and treatments. The human non-small cell lung cancer cells, A549, H1299, H460, human breast cancer cells, MCF-7, and human colon cancer cells, Colo-205, HT-29, were obtained from National Center for Cell Science, India. Drug surviving-MCF-7 cells (DS-MCF-7) were drug-resistant subclone of MCF-7 cells. Cells were routinely maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37 1C in a humidified incubator containing 5% CO 2 . Cells were treated with different concentrations of cisplatin, doxorubicin, etoposide and H 2 O 2 (Sigma, St. Louis, MO, USA) for different time points to select the optimum resistance or apoptotic dose. To evaluate the involvement of p38 mitogen-activated protein kinase (p38MAPK), JNK and ATM, cells were pre-treated with a specific p38MAPK inhibitor (SB203580; 10 mM, Calbiochem, Gibbstown, NJ, USA), JNK inhibitor (SP600125; 10 mM, Calbiochem) 90 min before treatment and with an ATM inhibitor (Wortmanin; 20 mM and KU55933; 10 mM, Calbiochem) 30 min before drug treatment. To neutralize druginduced oxidative stress, cells were pre-treated with N-acetyl cysteine (NAC; 40 mM, Sigma) for 1 h before drug treatment. To validate that PIASg oxidation leads to ubiquitin-mediated degradation, cells were pre-exposed with a proteasome inhibitor (MG132; 10 mM, Calbiochem) for 2 h before drug treatment.
Flow cytometry and confocal imaging. For the determination of cell death, cells were stained with 7-AAD and Annexin-V-FITC and analyzed on a flow cytometer (FACS Calibur, Beckton Dickinson, Mount View, CA, USA). For the assessment of cellular ROS, cultured cells or sensitive as well as resistant EAC cells, aseptically drawn within 2 h of drug treatment from the peritoneal cavity of tumor-bearing mice, were incubated for 20 min at 37 1C in the dark with 10 mM of dichlorofluorescindiacetate (DCFH-DA, Sigma). 48 DCF fluorescence was measured flow cytometrically (Beckton Dickinson FACScan) and subjected to analysis using Cell Quest 3.2 (Beckton Dickinson) software. The probe was excited at 488 nm, and emission was measured through a 530 nm band-pass filter.
For confocal microscopy, cells were grown on sterile glass coverslips at 37 1C for 24 h. Cells after treatment were washed briefly with PBS and fixed with 4% formaldehyde for 20 min at 37 1C. Thereafter, cells were blocked for 2 h in a blocking buffer (10% BSA in PBS) and then additionally incubated for another hour in PBS with 1.5% BSA containing anti-p65NFkB, p-ATM and IKKg (Santa Cruz, Santa Cruz, CA, USA). After washing in PBS, cells were incubated with FITC-or rhodamine-conjugated secondary antibodies in PBS with 1.5% BSA for 45 min at 37 1C in the dark. DAPI or PI was used for nuclear staining. Coverslips were washed with PBS and mounted on microscopy glass slides with 90% glycerol in PBS. Images were acquired using a confocal microscope (Carl Zeiss, Jena, Germany).
Co-immunoprecipitation and immunoblotting. For western blot analysis, the cell lysates or the particular fractions (nuclear/cytoplasmic) were separated by SDS-PAGE, transferred to nitrocellulose membrane and visualized by chemiluminescence. [49] [50] [51] [52] For the determination of direct interaction between two proteins, the co-immunoprecipitation technique was employed. The immunopurified proteins were then detected by western blot using a specific antibody (Santa Cruz). Equal protein loading was confirmed with an aactin/Histone H1 antibody (Santa Cruz).
Plasmid, siRNA, transfections and RT-PCR. The cDNA encoding p65NFkB, DN-IKKa, DN-IKKb and IkBa-32A/36A (IkBa super-repressor (IkBa-SR), kind gift from Dr. J Didonato, The Cleveland Clinic), were subcloned into pcDNA3.1 plasmids. The plasmid encoding PIASg and PIASgCA-cDNA (the catalytic active residues of PIASg-Cys 342 and Cys 347 are mutated to alanine) and IKKy mutant clones was a generous gift from Dr. Shigeki Miyamoto, Wisconsin Institutes Medical Research. pcDNA3.1 ( þ ) Flag-His-ATMwt-cDNA (plasmid 31985) was procured from Addgene (Cambridge, MA, USA). An siRNAresistant ATM-cDNA allele was constructed from ATM-cDNA with three base changes in the siRNA-targeting site (nucleotides 606-615 of ATM, 5 0 -CGGAGCTGATTGTAACAACA-3 0 to 5 0 -CGGAGCCGATTGCAATAACA-3 0 ), which altered codon usage but did not change the amino acid sequence. The sequence of the specific ATM-siRNA used were 5 0 -GUUGCUACAAUCAGCUCCG-3 0 , Antisense 5 0 -GGAGCUGAUUGUAGCA AC-3 0 . The plasmids were introduced separately into cells using lipofectamine-2000 (Invitrogen, Carlsbard, CA, USA). Isolation of stably expressing clones was obtained by limiting dilution and selection with G418 sulfate (Cellgro, Kansas City, MO) at a concentration of 1 mg/ml. Cells were transfected with 300 pmole of ATM/JNK-/p38MAPK-/PIASg-/MKP1-/MKK4-/ control-ds-si-RNA and lipofectamine-2000 separately for 12 h. The mRNA and protein levels were determined by RT-PCR and western blotting. Two micrograms of total RNA, extracted with TRIzol reagent (Invitrogen), was reverse transcribed and then subjected to PCR with enzymes and reagents of the RTplusPCR system (Eppendorf, Hamburg, Germany) using a GeneAmp PCR system 2720 (Applied Biosystems, Foster City, CA, USA). 52 Animal and tumor model. BALB/c mice (NCLAS, Hyderabad, India) weighing 20-25 g were maintained in temperature-controlled room with light-dark cycle. Mice were intra-peritoneally (i.p) injected with 1 Â 10 5 exponentially grown cisplatin-sensitive or resistant Ehrlich's ascites carcinoma (EAC) cells. 22, 23 EAC-P and EAC-V were stable cell lines generated from EAC-sensitive cells upon transfection with PIASyWT-cDNA or empty vector and subsequently selected with G418. Similarly, resistant EAC-PIASyCA was generated from resistant EAC cells transfected with PIASyCA clone. For in vivo experiments, 14 days post tumor inoculation, mice were treated with a cumulative dose of 9 mg/kg body weight cisplatin where 3 mg/kg body weight was i.p injected on day 15, 19 and 21. At regular time interval, the abdominal periphery was measured and then the animals were killed to analyze tumor volume, tumor cell number and tumor cell apoptosis. The EAC cells were isolated from the peritoneal cavity of tumor-bearing mice (control or treated). Two to three milliliters of sterile PBS was injected into the peritoneal cavity of the mice, and the peritoneal fluid containing the tumor cells was withdrawn, collected in sterile Petri dishes and incubated at 37 1C for 2 h. The cells of macrophage lineage adhered to the bottom of the Petri dishes. The nonadherent population was aspirated out gently and washed repeatedly with PBS. EAC cells were then separated from other non-adherent contaminating cells by FACS (fluorescence-activated cell sorter). More than 98% of this separated cell population was CD3/CD14/CD19/CD56 negative as was determined by a flow cytometer. Moreover, these cells were morphologically characterized as EAC by Wright staining and viability was assessed to be 495% by Trypan Blue dye exclusion. A portion of tumor cells was subjected to western blot determination of PIASg, p-ATM, p65NFkB, p-JNK and caspase-3. Each experimental set consisted of 10 animals. All animal experiments were performed following 'Principles of laboratory animal care' (NIH publication No. 85-23, revised in 1985) as well as Indian laws on 'Protection of Animals' under the prevision of authorized investigators.
Statistical analysis.
Values are shown as standard error of mean (S.E.M.). Data were analyzed and, when appropriate, significance of the differences between mean values was determined by a Student's t test. Results were considered significant at Po0.01.
